Patrick Campbell

An analysis of WHI data indicates social isolation and loneliness were associated with significant increases in risk of major cardiovascular disease, even after adjustment for other clinical risk factors.

A retrospective review of ASCVD risk factors at baseline and 1 year after initiating hormone therapy among transgender adolescents suggests the increased risk of cardiovascular disease seen among this population could be driven by increased prevalence of baseline risk factors.

Pooled data from 10k women in the Lifetime Risk Pooling Project suggests premature menopause was associated with a 40% increase in risk of coronary heart disease.

Analysis of the UK Biobank cohort details a graded increase in risk of cardiovascular and renal events across the glycemic spectrum, including among patients with prediabetes.

Hear from Deepak Bhatt, MD, MPH, on a systematic review and meta-analysis of SGLT2 inhibitor trials examining the effects of the class on heart failure across multiple subgroups, including those with preserved ejection fraction.

An analysis of patient and clinician responses to surveys within BOAT-AF suggests many were willing to consider DOACs but were never prescribed anticoagulation and also provides insight into how trends in this cohort compared to those in the ACC's PINNACLE registry.

A pooled risk simulation of phase 3 data of bempedoic acid suggests the first-in-class ATP citrate lyase inhibitor could reduce risk of cardiovascular events in patients with established cardiovascular disease and elevated LDL-C.

Analysis of data from the FIDELIO-DKD trial suggests use of finerenone was associated with a nearly 30% reduction in new-onset atrial fibrillation among patients within the phase 3 trial.

A comparison of annual mortality rates related to cancer and cardiovascular disease is shedding light on the impact of the obesity epidemic on progress against both since 1999.

Results of RADIANCE-HTN TRIO suggest ultrasound renal denervation could improve blood pressure control in patients with refractory hypertension, suggesting RDN was associated with a mean reduction of 8 mmHg from baseline a 4.5 mmHg improvement over sham procedure.

An analysis of 9 trials examining SGLT2 inhibitors in patients with heart failure provides insight into the effects of the agents across the spectrum of heart failure, including those with decreased eGFR and preserved ejection fraction.

An analysis of FIDELIO-DKD indicates use of finerenone was associated with significant reductions in risk of new-onset atrial fibrillation in patients with type 2 diabetes and chronic kidney disease.

Results of a well-being study presented at ACC.21 paint a grim picture related to the impact of COVID-19 on burnout and well-being among cardiology professionals. We sat down with lead investigator Laxmi Mehta, MD, for further perspective on the issue.

A new analysis of the SCORED and SOLOIST trials suggests sotagliflozin could provide substantial benefit for reducing risk of cardiovascular death and worsening heart failure among patients with HFrEF and HFpEF.

An ACC.21 study assessing the risk of adverse cardiovascular and renal outcomes found a graded increase in risk across the entire glycemic spectrum, including prediabetic levels.

Hear from Muthiah Vaduganathan, MD, MPH, as he discusses the results of an analysis of data within the GWTG-HF registry that details gaps in care and management of heart failure patients with comorbid kidney disease.

The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.

Data from the FLOWER-MI study suggest fractional flow reserve-guided PCI provided no benefit versus angiography-guided PCI for risk of death, MI, or urgent revascularization among STEMI patients with multivessel disease.

As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.

A secondary analysis of the STRENGTH trial from ACC.21 is calling into question the apparent CV benefits of other fish oil-based agents in patients with elevated triglycerides.

An analysis of STOP AF First presented at ACC.21 details the quality of life improvements observed with cryoablation versus antiarrhythmic drugs as initial treatment for atrial fibrillation.

Data from post hoc analyses of REDUCE-IT indicate patients with increased on-treatment levels of EPA had a lower risk of heart failure and new hospitalization for heart failure when compared to their counterparts with the lowest on-treatment EPA levels.

Results of the LAAOS III trial provide evidence suggesting left atrial appendage occlusion could reduce risk of ischemic events by nearly a third and also reduce risk of stroke by more than 40% in patients with atrial fibrillation.

The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.

The PARADISE-MI study missed achieving a statistically significant reduction in its primary endpoint, but offers insight into the effects of sacubitril/valsartan in patients with a history of acute MI.

A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.

An analysis of nearly 2 million patients suggests an increased BMI around the age of 18 was linked to a graded increase in the risk of ischemic stroke in midlife, regardless of diabetes status.

An analysis of data from more than 12k women suggests use of DXA scans can help predict women with increased risk of ASCVD events and also sheds light on the relationship between osteoporosis and cardiovascular health.

An analysis of data from more than 250k kidney transplant patients details the increased risk of mortality and graft failure according to diabetes status among these patients.

The latest study from Penn Medicine's Nudge Unit is detailing the impact of time of appointment on the probability of receiving a prescription for statin therapy at primary care clinics among patients with an indication for statin therapy.